BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

892 related articles for article (PubMed ID: 36877356)

  • 1. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.
    Beishenaliev A; Loke YL; Goh SJ; Geo HN; Mugila M; Misran M; Chung LY; Kiew LV; Roffler S; Teo YY
    J Control Release; 2023 Jul; 359():268-286. PubMed ID: 37244297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody drug conjugates: Making 1+1>2.
    Gu Y; Wang Z; Wang Y
    Acta Pharm Sin B; 2024 May; 14(5):1965-1986. PubMed ID: 38799638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
    Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
    Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
    Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
    Zhang T; Lin Y; Gao Q
    Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
    Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
    Dabkowska A; Domka K; Firczuk M
    Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
    Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
    Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
    Kumari S; Raj S; Babu MA; Bhatti GK; Bhatti JS
    Arch Pharm Res; 2024 Jan; 47(1):40-65. PubMed ID: 38153656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.
    Sellmann C; Doerner A; Knuehl C; Rasche N; Sood V; Krah S; Rhiel L; Messemer A; Wesolowski J; Schuette M; Becker S; Toleikis L; Kolmar H; Hock B
    J Biol Chem; 2016 Nov; 291(48):25106-25119. PubMed ID: 27694443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of precision antibody conjugates using proximity-induced chemistry.
    Cao YJ; Yu C; Wu KL; Wang X; Liu D; Tian Z; Zhao L; Qi X; Loredo A; Chung A; Xiao H
    Theranostics; 2021; 11(18):9107-9117. PubMed ID: 34522229
    [No Abstract]   [Full Text] [Related]  

  • 19. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
    Schwach J; Abdellatif M; Stengl A
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.